Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Epigenetic changes in patients with multiple sclerosis.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Assessment of statistical significance and clinical relevance.
Pediatric multiple sclerosis.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Prospective memory, emotional valence, and multiple sclerosis.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package

Pages